Clinical Trial Update: Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing the impact of empagliflozin (SGLT2 inhibitor) on urinary supersaturations in people with kidney stones.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Stones

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Kidney Stone | Phase 2 | Status: COMPLETED